All News

PSA%20026.jpg

Long-Term Benefits of Ixekizumab in Psoriatic Arthritis

Jack Cush, MD

The SPIRIT-P1 study has demonstrated the safety and efficacy of ixekizumab (an IL-17A antagonist) when given to adults w/ active psoriatic arthritis (PsA), and also demonstrating radiographic protection and improvement in skin outcomes as well. 

Read Article
SPA.spectrum.jpg

SPARTAN ACR20 Recommendations on Spondyloarthritis

Jack Cush, MD

SPARTAN has compiled a list of presentations and sessions worth seeing if you are interested in ankylosing spondylitis, spondyloarthritis and related disorders.

Read Article
podcast logo

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Jack Cush, MD

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article
pssfing.jpg

Abatacept in Early Systemic Sclerosis (ASSET study)

Jack Cush, MD

An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).

Read Article
PSS.hands_.Raynauds.jpg (keep)

FDA Invites Patient Input on Systemic Sclerosis Drug Development

Jack Cush, MD

While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.

Read Article
PsA.Hands_.jpg

Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis

Jack Cush, MD

The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.

Read Article
colitis.jpg

Vedolizumab Promising in Immune-Related GI Events

Jack Cush, MD

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

Read Article
podcast logo

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article
COVID.virus_.corona.jpg (keep)

Remdesivir FDA Approved for Hospitalized COVID-19

Jack Cush, MD

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Read Article
Covid lung pneumonia corona (keep)

Clinical Trial Boom or Bust in Severe COVID-19

Jack Cush, MD

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.



Remdesivir

Read Article
Exciting to hear about 5 trials for #GCA 1. ABAGART (#Abatacept) 2. METOGIA (#tocilizumab vs MTX) 3. SELECT (#upadacitinib) 4. MAVRILIMUMAB (#gmcsf i) 5. TiTIAN (#secukinumab) ⁦@VasculitisFound⁩ #vasculitis #vcrc https://t.co/DVvG5Ekfu9
KenWarringtonMD MdWarrington ( View Tweet)
RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0

Links:

Dr. John Cush RheumNow ( View Tweet)

Incidence & Risk VTE Among Pts RA Enrolled in Upadacitinib Trial Program https://t.co/zCuWHZXV4h #VTE #Upadacitinib balanced VTE across trial programme in the expected 0.5-0.8/100 pt yrs range - past VTE & BMI risk factors, no mention COX2s - is VTE Jak2 effect or class effect?

Links:

Peter Nash drpnash ( View Tweet)

Safety of nintedinib (NIN)in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%. RCT discontinuation in 16% & 8.7% https://t.co/v5NxwlHu37

Links:

Dr. John Cush RheumNow ( View Tweet)

PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz https://t.co/lnXrf12tjA

Links:

Dr. John Cush RheumNow ( View Tweet)

Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr. Jack Cush discusses triage Rheumatology; Im Not Stupid; & Swollen but Not Painful iTunes https://t.co/FHJv01Sb3a SoundCloud https://t.co/fceBeXGu09

Links:

Dr. John Cush RheumNow ( View Tweet)

Empty out your medicine cabinets. Sat Oct 24th is DEA "TAKE BACK" day. Dispose of unused, unwanted, controlled drugs, narcotics, e-cigarettes. Theyll take your tablets, capsules, patches, pens, liquids (BUT NOT syringes, sharps, illegal drugs) Where? https://t.co/oDMYHl3mgI

Links:

Dr. John Cush RheumNow ( View Tweet)

Lilly has announced results of Phase 2 SERENITY trial showing the IL-23 inhibitor, mirikizumab, was more effective than PBO at week 12 (PRO and endoscopic outcomes) in moderate to severe active Crohn's disease. Efficacy continued out to week 52 https://t.co/n8Mdeonmas

Links:

Dr. John Cush RheumNow ( View Tweet)

SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?

Dr. John Cush RheumNow ( View Tweet)

Not sure why this study was done...BUT... Tociiizumab was studied in 104 hand osteoarthritis and after 12 weeks, TCZ was equivalent to Placebo in achieving100mm VAS pain reduction (-9.9 vs -7.9), but TCZ had numerically more adverse events https://t.co/NYujNQbjvm

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×